Sarcopenia Is Associated With Severe Treatment Toxicity and Mortality in Older Adults With Advanced Cancer: A Secondary Analysis.
Lindsey J Mattick, Mostafa Mohammed, Chin-Shang Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This secondary analysis of a randomized controlled trial examined the impact of sarcopenia on treatment outcomes in 161 older adults (≥ 70 years) with advanced cancer. The study found that 57% of participants had sarcopenia, with 59% classified as severe. Sarcopenia was linked to a 2.24-fold increased likelihood of severe non-hematologic toxicities and a 1-year survival rate of 46%, compared to 60% in those without sarcopenia.
Key findings
- 57% of older adults with advanced cancer met criteria for sarcopenia.
- Patients with sarcopenia had a 2.24-fold increased likelihood of severe non-hematologic toxicities.
- 1-year survival was 46% for those with sarcopenia versus 60% for those without.
Why it matters
Understanding the association between sarcopenia and treatment toxicity or mortality is crucial for optimizing care in older cancer patients. This highlights the need for comprehensive assessments of muscle strength and performance in this population.